Botulinum toxin for treatment of jaw opening dystonia in Hallervorden-Spatz syndrome.
Dressler
D
D
Department of Neurology, Rostock University, Rostock, Germany. dirk.dressler@med.uni-rostock.de
Wittstock
M
M
Benecke
R
R
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D020821:Dystonic Disorders / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007571:Jaw Diseases / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006211:Pantothenate Kinase-Associated Neurodegeneration / Q000150:complications*
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A